Pfizer and Sun settle Bosulif dispute
Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
Pfizer sued Sun in 2017 at the US District Court for the District of Delaware, alleging that the Indian company’s proposed Bosulif (bosutinib) generic infringed two of its patents.
According to new court filings, the parties have now reached a settlement and licensing agreement that will bring the litigation to an end.
Terms of the settlement were not disclosed.
Sun filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration in November 2016, indicating its intention to develop generic Bosulif products.
Pfizer sought a court declaration that the products described in the ANDA would infringe its two patents and an injunction blocking the generics.
It is not the first time the companies have been embroiled in patent litigation.
In April this year, LSIPR reported that Sun had filed a complaint at the US District Court for the District of New Jersey over an extended-release formulation of Lyrica (pregabalin).
According to the complaint, Pfizer’s product infringed US patent number 9,393,205, covering a gastroretentive tablet comprising pregabalin.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.